Claudio Pisano

Claudio Pisano

Auto-generated profile, based on publicly available information

Claudio Pisano

Authors' Affiliations: 1Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori; 2Molecular Pathology Unit, Ospedale Niguarda Ca' Grande, Milan; and 3Sigma-Tau S.p.A., Pomezia, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Blood
Verified
Journal Article
Closed access
PDF file
Enrico GarattiniEnrico Garattini
Enrico Garattini
EPEdoardo Parrella
Edoardo Parrella
Luisa DiomedeLuisa Diomede
Luisa Diomede
MGMaurizio Gianni'
Maurizio Gianni'
YKYesim Kalac
Yesim Kalac
CPClaudio Pisano
Claudio Pisano
Retinoid-related molecules (RRMs) are derivatives of retinoic acid and promising antileukemic agents with a mechanism of action different from that of other common chemotherapeutics. Here, we describe a novel chemical series designed against the RRM prototype, CD437. This includes molecules with apoptotic effects in acute promyelocytic leukemia and other myelogenous leukemia cell lines, as well as ST2065, an RRM with antagonistic properties. The most interesting apoptotic agent is ST1926, a compound more powerful than CD437 in vitro and orally active in vivo on severe combined immunodeficiency (SCID) mice that received transplants of NB4 cells. ST1926 has the same mechanism of action of CD437, as indicated by the ability to trans-activate retinoic acid receptor γ, to induce the phosphorylation of p38 and JNK, and to down-regulate the expression of many genes negatively modulated by CD437. ST1926 causes an immediate increase in the cytosolic levels of calcium that are directly related to the apoptotic potential of the RRMs considered. The intracellular calcium elevation is predominantly the result of an inhibition of the mitochondrial calcium uptake. The phenomenon is blocked by the ST2065 antagonist, the intracellular calcium chelator BAPTA (1,2 bis (2-aminophenoxy) ethane-N, N, N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester), and by high concentrations of calcium blockers of the dihydropyridine type, compounds that suppress ST1926-induced apoptosis.

8 October 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SCSam Cross-Knorr
Sam Cross-Knorr
SLShaolei Lu
Shaolei Lu
KPKimberly Perez
Kimberly Perez
SGSara Guevara
Sara Guevara
KBKate Brilliant
Kate Brilliant
DCDevasis Chatterjee
Devasis Chatterjee
Background: A major obstacle in treating colorectal cancer (CRC) is the acquired resistance to chemotherapeutic agents. An important protein in the regulation of cancer cell death and clinical outcome is Raf kinase inhibitor protein (RKIP). In contrast, activated signal transducer and activator of transcription 3 (STAT3) is a protein that promotes tumor cell survival by inhibiting apoptosis and has an important role in cancer progression in many of cancer types. The aim of this study was to evaluate the regulation of RKIP and STAT3 after treatment with clinically relevant chemotherapeutic agents (camptothecin (CPT) and oxaliplatin (OXP)) and the cytokine interleukin-6 (IL-6) in HCT116 colon cancer cells as well as evaluate the association between RKIP and STAT3 with clinical outcome of Stage II colon cancer patients.Methods: HCT-116 colon cancer cells were treated with CPT, OXP, and IL-6 separately or in combination in a time and dose-dependent manner and examined for phosphorylated and non-phosphorylated RKIP and STAT3 via Western blot analysis. STAT3 transcriptional activity was measured via a luciferase reporter assay in HCT116 cells treated with CPT, IL-6 or transfected with JAK 1, 2 separately or in combination. We extended these observations and determined STAT3 and RKIP/ pRKIP in tumor microarrays (TMA) in stage II colon cancer patients.Results: We demonstrate IL-6-mediated activation of STAT3 occurs in conjunction with the phosphorylation of RKIPin vitroin human colon cancer cells. OXP and CPT block IL-6 mediated STAT3 activation and RKIP phosphorylation via the inhibition of the interaction of STAT3 with gp130. We determined that STAT3 and nuclear pRKIP are significantly associated with poor patient prognosis in stage II colon cancer patients.Conclusions: In the analysis of tumor samples from stage II colon cancer patients and the human colon carcinoma cell line HCT116, pRKIP and STAT3, 2 proteins potentially involved in the resistance to conventional treatments were detected. The phosphorylation of pRKIP and STAT3 are induced by the cytokine IL-6 and suppressed by the chemotherapeutic drugs CPT and OXP. Therefore, these results suggest that STAT3 and pRKIP may serve as prognostic biomarkers in stage II colon cancer patients and may improve chemotherapy.

28 July 2010 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CPClaudio Pisano
Claudio Pisano
LVlore vesci
lore vesci
FMFerdinando Maria Milazzo
Ferdinando Maria Milazzo
MGMario Berardino Guglielmi
Mario Berardino Guglielmi
RFRosanna Foderà
Rosanna Foderà
FZFranco Zunino
Franco Zunino
Purpose: Acetyl-l-carnitine (ALC) plays a relevant role in energy metabolism and stress response because of its function in the complex metabolic system regulating the acetyl-CoA levels that provide a source of acetyl groups for metabolic and acetylation-regulated processes. Because acetylation may influence p53 activity/stability and, therefore, the response to platinum compounds, this study was designed to investigate the effect of ALC in combination with platinum compounds. Experimental Design: The antiproliferative and antitumor activity studies were done in a panel of human tumor cell lines with functional or defective p53. The antimetastatic drug efficacy was investigated in the s.c. growing H460/M tumor subline, which is able to generate lung metastases. Results: ALC enhanced the sensitivity to cisplatin of tumor cells with functional p53. The sensitization by ALC was reflected in an improved in vivo antitumor efficacy of the combination over cisplatin alone in wild-type p53 lung tumors. ALC did not increase the cisplatin efficacy in the p53-mutant SW620 tumor. ALC exhibited a significant antimetastatic activity, and this effect was better exploited in combination with the histone deacetylase inhibitor, ST3595. The in vivo ALC/cisplatin combination caused the activation of p53, associated with protein acetylation and induction of target genes. Conclusions: ALC was effective in enhancing the antitumor potential of platinum compounds in wild-type p53 tumors. ALC, alone and in combination with a histone deacetylase inhibitor, exhibited an outstanding antimetastatic activity. Both effects, likely mediated by protein acetylation, may have implications for platinum-based therapy and combinations with histone deacetylase inhibitors. Clin Cancer Res; 16(15); 3944–53. ©2010 AACR.

13 April 2012 in Biochemical Pharmacology
Verified
Journal Article
Closed access
GCGiuliana Cassinelli
Giuliana Cassinelli
VZValentina Zuco
Valentina Zuco
GPGiovanna Petrangolini
Giovanna Petrangolini
MCMichelandrea De Cesare
Michelandrea De Cesare
MTMonica Tortoreto
Monica Tortoreto
FZFranco Zunino
Franco Zunino

1 October 2003
Verified
Journal Article
Closed access
GPGiovanna Petrangolini
Giovanna Petrangolini
GPGraziella Pratesi
Graziella Pratesi
MCMichelandrea De Cesare
Michelandrea De Cesare
RSRosanna Supino
Rosanna Supino
CPClaudio Pisano
Claudio Pisano
FZFranco Zunino
Franco Zunino

1 June 2008 in European Journal of Cancer
Verified
Journal Article
Closed access
CPClaudio Pisano
Claudio Pisano
VZValentina Zuco
Valentina Zuco
MCMichelandrea De Cesare
Michelandrea De Cesare
VBValentina Benedetti
Valentina Benedetti
LVLoredana Vesci
Loredana Vesci
FZFranco Zunino
Franco Zunino